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include the total direct and indirect costs associated with 
the consequences and management of side effects. 
Unfortunately, no randomized, prospective, clinical trial 
comparing AmBd and a specific lipid formulation has 
ever been performed and therefore we must base our 
evaluations on open-label studies, with or without 
historical conventional amphotericin B controls. Most 
animal model studies have suggested that larger doses of 
the lipid preparations are required to produce 
therapeutic effects equivalent to AmBd. 
The adverse events reported in patients administered 
lipid-based formulations of amphotericin B are similar 
to those associated with conventional formulations, how- 
ever the prevalence is significantly reduced. Immediate 
toxic reactions are less common, although fever, chills 
and flank pain may still be seen within the first few days 
of treatment. These effects are generally transient and 
respond well to treatment with hydrocortisone. Nephro- 
toxicity has not disappeared but it is much less common 
in patients treated with lipid-based amphotericin B and 
furthermore, individuals who develop renal impairment 
during treatment with a conventional formulation may 
be improved or stabilized when a lipid-based formu- 
lation is substituted. This is an important consideration 
for the treatment of mycoses in critically ill patients who 
may be renally insufficient through trauma or under- 
lying illness. 
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Invasive aspergillosis remains a major cause of mor- 
bidity and mortality in immunosuppressed patients. 
Even with the use of amphotericin B, which has been the 
standard therapy for critically ill patients with this 
disease, outcomes of invasive aspergillosis in high-risk 
patients remain unacceptably high. New classes of anti- 
fungal agents including the azole antifungals have been 
developed with activity against this lethal pathogen. 
The need for new therapies against Aspergillus was 
demonstrated in a review of 595 cases of invasive asper- 
gillosis. Antifungal failures were common: progression 
of disease despite therapy occurred in 36% while com- 
plete antifungal responses were noted in only 27%. 
Overall, mortality in invasive aspergillosis remains over 
60% but in high-risk patients such as those undergoing 
allogeneic bone marrow transplantation mortality is 
even greater, approaching 90%. Similarly, in patients 
with disseminated or central nervous system infection, 
mortality rates are over 90%. 
Early imidazole and triazole antifungals including 
fluconazole lacked Aspergillus activity. Itraconazole 
does have activity against Aspergillus but it has not been 
extensively utilized in patients with proven infection due 
to the fact that it has only recently been introduced in 
an intravenousformulation-a feature essential to use 
in critically-ill patients-and due to its erratic absorp- 
tion, particularly in high risk patients such as those 
undergoing bone marrow transplantation or those with 
severe mucositis. Nevertheless, its activity has been 
demonstrated in patients with less severe immuno- 
suppression and for use in sequential therapy following 
initial courses of amphotericin B. 
Newer triazoles such as voriconazole, ravuconazole, 
and posaconazole have been introduced. These agents 
were developed specifically for activity against Aspergillus 
and demonstrate fungicidal activity against the organism. 
Both posaconazole and ravuconazole have activity in 
animal models of aspergillosis and posaconazole has 
been effective in clinical studies using an oral formu- 
lation of drug. 
Voriconazole, which has recently been approved for 
clinical use, is available in both intravenous as well as a 
well-absorbed oral formulation. Recent studies demon- 
strate the efficacy of voriconazole as primary therapy 
of invasive aspergillosis, including patients with dis- 
seminated infection and central nervous system disease. 
In a comparative study with amphotericin B followed by 
other licensed therapy, voriconazole produced complete 
or partial responses in 53% as compared to 32% 
receiving amphotericin B. Importantly, survival was 
significantly improved in patients receiving voriconazole, 
with 71% survival as compared to 58% survival of 
patients receiving amphotericin B followed by other 
therapies. 
The activity of these newer azoles has increased 
interest in combinations of antifungal therapies along 
with immune reconstitution to further improve responses. 
Recent studies have not shown the antagonism between 
these azoles and polyene antifungals that was demon- 
strated in animal models using early azoles such as 
ketoconazole. While clinical utility of combination 
therapy has not been proven to be of benefit, preclinical 
studies suggest improved activity of azoles with the 
echinocandins in producing sterile tissues and com- 
binations with echinocandins, polyenes and azoles have 
been suggested to have a potential benefit. 
In summary, the new azoles offer activity specifically 
targeted for moulds like Aspergillus. Recent studies 
suggest that these agents may become the new standard 
for primary therapy of this disease and combinations of 
antifungal agents, including the azoles, may begin to 
improve the outcomes of this often lethal disease. 
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